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Background: Few data exist with respect to the occurrence of chronic side effects
due to antiepileptic drugs (AED) in routine clinical practice.
Objective: To evaluate the prevalence of subjective complaints which patients with
epilepsy regard as side effects of their AED treatment in a community-based popula-
tion.
Methods: Cross-sectional study. Subjects were identified through the database of
AED-use in the pharmacies in a suburban area in The Netherlands. Respondents
completed a brief questionnaire about their epilepsy, including a checklist with 30
complaints, which are common in AED users.
Results: We present data of 346 responding adults with treated epilepsy from a
population of 107,000 adult inhabitants. Eighty percent was using monotherapy, with
few patients taking new AEDs. Almost 60% of the patients reported complaints
probably due to side effects in at least three domains. General CNS-related side
effects were reported most often; memory problems (21.4% of the patients) and
fatigue (20.3%) were dominant. Polytherapy was associated with more side effects
than monotherapy. We identified differences in profiles of complaints between
valproate, carbamazepine and phenytoin monotherapy. Complaints were not sub-
stantially associated with ongoing seizures or other treatment factors.
Conclusions: The majority of patients taking AEDs for epilepsy think they have side
effects form their drugs, even when seizures were in remission and when mono-
therapy was used. Our findings suggest a need to improve monitoring of complaints of
side effects of AEDs and to explore the feasibility of interventions aimed at reduction
of such complaints in everyday clinical practice.
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Antiepileptic drug (AED) treatment aims at control-
ling seizures without inducing side effects. All AEDs
have the potential to cause central nervous system
(CNS) dysfunction and other side effects.1—3
Patients consider avoiding side effects a very impor-
tant issue in epilepsy treatment.4 Side effects are
also a crucial factor determining the willingness of
patients to take drugs at long-term.5 There is no
generally accepted method of assessment for many
side effects related to the use of AEDs (such as
fatigue or dizziness). Gold standards for quantifica-
tion of occurrence, severity and tolerability of side
effects are seldom available.2,6 Therefore, the clin-
ician often has to rely in medical decision-making on
the patient’s subjective reporting.
Most information about the impact of side effects
has been obtained from clinical trials. This informa-
tionmay have been biased. In- and exclusion criteria
are often stringent. The side effects are those
reported in a well-structured environment of a trial,
which is distinctly different from normal clinical
practice. The monitored side effects are the effects
at short-term, given the relatively short duration of
clinical trials. Furthermore, physicians may be more
alert to detect objective, biological side effects
(e.g. rash, weight gain) than subjective side effects.
We embarked on a cross-sectional study, to eval-
uate complaints associated with the use of AEDs
with maximum effort to avoid selection bias. We
identified adult AED users in one area through local
pharmacy databases. We mailed all identified AED
users a questionnaire asking them to confirm that
they had epilepsy. We report a cross-section of the
respondents’ subjective complaints that are prob-
ably due to their AED treatment. We had no access
to clinical records, hence information with respect
to diagnosis and treatment was limited.Methods
Seventeen of the 18 outpatient pharmacies in the
Gooi-Noord region, a suburban area South-East of
Amsterdam with approximately 107,000 inhabitants
>15 years, co-operated. We identified all phar-
macy-clients using AEDs in the pharmacy databases.
The only pharmacy which did not participate (due to
lack of time) has about 5000 clients. Patients with
epilepsy living in institutions, such as nursing homes
or homes for mentally retarded were excluded.
After identification, the pharmacies mailed a ques-
tionnaire to all eligible clients (>15 years of age),
with an accompanying letter explaining the purpose
of the study and enclosing a prepaid return envel-ope. Patients who responded remained anonymous
to the investigators. A number of articles in local
newspapers paid attention to the study, encouraging
people to respond. For medical ethical reasons, we
sought no further contact with non-responders. The
Medical Ethics Commission of the Gooi-Noord Hos-
pital approved the study.
In the questionnaire, the subjects were firstly
asked to confirm that they used AEDs for epilepsy,
and not for another reason. Subjects without epi-
lepsy or those who were not willing or able to
complete the questionnaire were asked to return
it without further comment in the prepaid envel-
ope. The questionnaire for respondents with epi-
lepsy focused on information about their epilepsy
and included a simple checklist to report side
effects of the treatment (see addendum). The
responses on the checklist were categorised from
‘none’, via ‘mild’ and ‘moderate/serious’ to ‘very
serious’.
Specific questions addressed the following issues:
Did you have any (major or minor) seizures in the
past 2 years, if so, how many seizures (major and
minor rated separately) in the past year?
Do you find your ongoing seizures acceptable, mean-
ing that you don’t consider it necessary to do some-
thing about them when this was possible?
Have you discussed your epilepsy with a physician in
the past 2 years, if so whenwas the last visit and how
many times this last year did you discuss epilepsy
with your treating physician? Who prescribes the
medication, do you have personal contact with your
prescribing doctor or do you receive repeat recipes
without further personal contact (e.g. from the
doctors secretary)?
From the pharmacy database we received data on
age, gender, and AEDs the respondent was using at
the time of completing the questionnaire. However,
these databases did not provide information about a
client’s diagnosis. Hence, further information with
respect to the validity of the diagnosis, the average
duration of epilepsy at the time of the questionnaire
and the length of time the patients were treated
with the actual drugs, co-morbidity, or classification
of epilepsy or seizures was not available. Becausewe
expected that most patients taking AEDs for another
reason than epilepsy, would in fact suffer from psy-
chiatric disorders for which AEDs can be indicated,
we excluded these patients from our study.
Statistical analysis
Because of the exploratory character of this study,
when analysing the responses to the side effects
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sent (‘none’ or ‘mild’) or present (‘moderate/ser-
ious’ or ‘very serious’). Data were analysed using
SPSS, with standard parametric (descriptive) statis-
tics. For testing the differences between the several
drug groups non-parametric analysis of variance was
used, based on the Kruskall Wallis test. If this
yielded statistical significance, post hoc compari-
sons between the separate groups was allowed,
using Mann—Whitney U tests. In addition correla-
tional analysis was performed to inspect which fac-
tors were related to side effect complaints, using
linear regression analysis. For correlations Spear-
man’s rho was used. All p levels were set at .05.
To evaluate whether our sample was biased by
non-response, basic demographic characteristicsTable 1 General characteristics of the patient group (N =
Characteristic
Age
Male
Epilepsy (%)
Are the seizures acceptable?
Type of treatment
Type of AEDs (all type of treatments)
Type of AEDs (only monotherapy)
Who prescribes the AED?
Treatment frequency
Was epilepsy discussed with doctor during the last year?
S.D.: standard deviation. AED: antiepileptic drug.and data on AEDS use of the non-responders (with
andwithout epilepsy, as for these subjects therewas
no confirmation of the diagnosis) were inspected.
This showed no differences with respect to age,
gender or type of AEDs: non-responders: mean
age 51.0 years (S.D. 16); responders 51.9 years;
S.D. 18.9; p = .84; gender: men 54% (50.4% for
the responders; p = .93); AEDs 77% monotherapy;
23% combination therapy (responders: 80.9%,
19.1%, respectively; p = .63).Results
The database identified 692 patients using AEDs.
These patients all received a questionnaire of which346).
51.9 years (S.D. 18.9; range 16—94)
50.4%
In seizure remission > 2 years: 170 (51%)
Regular ‘large seizures’ 82 (24%) with
an average of 3.3 seizures/year
(S.D. 7.3, range 1—60)
Regular ‘minor seizures’ 131 (38%) with
an average of 75.7 seizures/year
(S.D. 248.3, range 1—1820)
Acceptable: 42% of the patients
Monotherapy: 80.9%
Combination therapy: 19.1%
Valproate: 34.1%
Carbamazepine: 30.9%
Phenytoin: 21.9%
Phenobarbitone: 10.4%
All benzodiazepines: 2.3%
Ethosuximide: 2.3%
Newer AEDs
Lamotrigine: 9.2%
Oxcarbazepine: 7.5%
Topiramate, gabapentin, vigababtrin
and levetiracetam all: <1%
Valproate: 28.7%
Carbamazepine: 24.7%
Phenytoin: 15.7%
Phenobarbitone: 3.7%
Newer AEDs
Oxcarbazepine: 5.6%
Lamotrigine: 2.5%
Combination therapy: 19.1%
Only specialists: 83.1%
Only general practitioner: 15.7%
Not in last year (only to get the
prescription): 24.3%
At least once in last year 75.7%
(on average 2.8 times a year; S.D. 4.5)
Yes 65.8%
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reported not to take the AEDs because of epilepsy
but for another reason (mainly psychiatric disorders
and— in a few cases —migraine). The remaining 399
patients reported to take the AEDs because of epi-
lepsy. Of these 399 patients with epilepsy, 53
refused or were unable to complete the question-
naire, leaving 346 (87%) completed questionnaires.
Table 1 shows the demographic and most impor-
tant clinical characteristics of the study group. The
relatively high mean age was caused by excluding
patients <15 years without an upper age limit. We
had no adequate data to classify their epilepsies.
About half of the patients reported to be in remis-
sion for >2 years. One-fourth of the patients had
‘major seizures’ (seizures with longer duration andTable 2 Subjective reported side effects (N = 346).
Area and type of side effecta
General CNS
Fatigue
Tiredness
General slowing
Headache
Dizziness
Motor problems
Tremor
Ataxia
Falling
Gastrointestinal complaints
Weight gain
Defecation problems
Loss of appetite
Nausea
Diarrhea
Weight loss
Cognition
Memory problems
Concentration difficulties
Speech problems
Language difficulties
Visual
Double vision
Mood and behaviour
Agitation/irritability
Depression
Cosmetic
Hair loss
Gum problems
Skin complaints
Sleep problems
Insomnia
a One patient may be reporting several side effects.
b Summary of both moderate and severe complaints.loss of consciousness such as partial complex sei-
zures and secondary generalised tonic-clonic sei-
zures) with an average of 3.3 seizures/year; one-
fourth reported to have ‘minor seizures’ (such as
absence seizures or myoclonic seizures) with an
average of 75.7 seizures/year (about 112 seizure
per week). Of the 166 reporting ongoing seizures,
42% considered their seizures acceptable. The large
majority used one AED. Valproate and carbamaze-
pine were the most commonly prescribed AEDs,
accounting for >50% of the drugs in monotherapy.
Some new AEDs (e.g. topiramate and levetiracetam)
had become available only very recently in the
Netherlands at the time of this study. Polytherapy
was related with seizure remission (Spearman’s rho
.14; p = .02) and with frequency of minor seizuresComplaintsb (%)
68.2 (overall CNS complaints)
20.3
18.8
12.1
8.9
8.1
31.5 (overall motor complaints)
13.3
13
5.2
33.2 (overall gastrointestinal complaints)
12.4
8.4
5.2
2.9
2.3
2.0
61.8 (overall cognitive complaints)
21.4
16.1
8.7
7.8
7.5 (overall visual complaints)
7.5
22.3 (overall mood/behaviour complaints)
14.8
7.5
20.4 (overall ‘cosmetic’ complaints)
7.2
7.8
5.4
8.7 (overall complaint about sleep)
8.7
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were statistically significant, the correlations of .14
and .28 were moderate. Although the majority of
the patients report regular appointments with a
specialist in the past year, about 15% only sees a
general practitioner and almost one-fourth had not
seen a physician for their epilepsy in the past year.
About one-third of the patients reported not to have
discussed their epilepsy with the treating physician
during the last year.
Table 2 summarises the results for the side effects
checklist. When analysed per patient, the number of
patients reporting side effects in at least three
different domains was 58%. This was not restricted
to respondents with ongoing seizures, i.e. both
patients in remission and patients with ongoing
seizures reported complaints (p = .46). The two
domains which yielded the highest prevalence of
complaints were general CNS-related complaints
(such as fatigue and dizziness) with 68% complaints
and cognitive complaints (62%). Within these
domains, the most frequently reported complaints
were memory problems (21%), fatigue (20%), tired-
ness (19%) and concentration difficulties (16%).
Subsequently, differences in side effect profile
were tested per antiepileptic drug in four groups
with>50 patients: patients on monotherapy valpro-
ate (VPA), carbamazepine (CBZ) or phenytoin (PHT)
and patients on polytherapy (29, 25, 16, and 19% of
the study group, respectively). Table 3 shows theTable 3 Differences per complaint between four groups:
phenytoin (PHT) monotherapy, and patients using polythera
Complaint Overall difference:
Chi-square based on
the Kruskall Wallis te
Fatigue 9.276; d.f. 3; p = .03
Ataxia 11.073; d.f. 3; p = .0
Nausea 8.389; d.f. 3; p = .04
Tiredness 10.047; d.f. 3; p = .0
General slowing 9.830; d.f. 3; p = .02
Concentration difficulties 8.253; d.f. 3; p = .04
Weight gain 8.040; d.f. 3; p < .05
The sign > indicates a statistically significant higher percentage ofareas in which these groups differed significantly.
Polytherapy was associated withmore side effects in
most domains. PHT was associated with more con-
centration difficulties compared to VPA, and VPA
and PHT with more weight gain compared to CBZ.
As the large effects of polytherapy may obscure
possible differences between VPA, CBZ and PHT, a
separate analysis has tested exclusively the differ-
ence between these three groups. Only for weight
gain the Kruskall Wallis overall non-parametric test
of variance yielded statistical significance (8.287;
p = .02). This is caused by more weight gain when
using VPA or PHT compared with CBZ.
Finally, we applied linear regression analysis to
inspect whether possible interfering factors, such as
ongoing seizures or type of care, were related to the
reported complaints. We used the two dominant
complaints: memory problems (21%) and fatigue
(20%) as dependent variables. We entered epilepsy
variables (number of ‘major seizures’/year, number
of ‘minor seizures’/year, 2-year seizure remission,
seizures acceptable or not?) and treatment vari-
ables (treatment by specialist or GP, frequency of
outpatient visits and whether the epilepsy had been
a discussion topic during the last year) as predictors.
For memory complaints a model was derived with
only two variables. In the first step the variable ‘2-
year seizure remission’ was entered (b = .16;
p < .001); in the second step ‘are the seizures
acceptable or not’ (b = .14; p = .002). The relation-patients using valproate (VPA), carbamazepine (CBZ),
py.
st
Differences between the four groups
(VPA, CBZ, PHT, polytherapy) based
on the Mann—Whitney U test
Polytherapy > CBZ (U = 1834; p = .02)
Polytherapy > PHT (U = 1041; p = .005)
1 Polytherapy > VPA (U = 2226.5; p = .007)
Polytherapy > CBZ (U = 1952.5; p = .02)
Polytherapy > PHT (U = 1170; p = .03)
Polytherapy > VPA (U = 2334; p = .03)
Polytherapy > PHT (U = 1184; p = .02)
2 Polytherapy > VPA (U = 2089; p = .02)
Polytherapy > CBZ (U = 1724.5; p = .003)
Polytherapy > VPA (U = 1995.5; p = .005)
Polytherapy > CBZ (U = 1789; p = .009)
PHT > VPA (U = 1799; p < .05)
Polytherapy > VPA (U = 2084.5; p = .01)
VPA > CBZ (U = 3234; p = .05)
PHT > CBZ (U = 1617; p = .004)
Polytherapy > CBZ (U = 2117.5; p = .02)
patients reporting problem for that specific area.
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Table 4 Summary of patient complaints (thresh-
old > 15% of the patients complaining) for valproate
(VPA), carbamazepine (CBZ) and phenytoin (PHT).
VPA (%) CBZ (%) PHT (%)
Fatigue 20.5 15.1
Tremor 20.5
Tiredness 18.3 17.5 23.5
Weight gain 21.8
Memory 19.4 20.1 27.4
Concentration
difficulties
16.3 25.5
Ataxia 23.3
Bold represents areas specific per drug.ship can be explained as follows: if the patient has
ongoing seizures and does not consider the seizures
acceptable there is a higher tendency to complain
about memory. The percentage explained variance
was extremely low (R2 = .04), indicating that even
these two variables have only a marginal relation-
ship with reported memory complaints.
For fatigue a similar outcome was obtained. The
model showed that the same two variables were
related to complaints about fatigue: if the patient
has ongoing seizures (b = .20; p < .001) and does
not consider the seizures acceptable (b = .11;
p = .04) there is a higher tendency to complain
about fatigue. Again, the percentage explained
variance was extremely low (R2 = .05).
Finally, in an attempt to find the characteristic
areas of side effect per antiepileptic drug, we sum-
marised the complaints per AED for the three drugs
with >50 patients included, i.e. monotherapy VPA,
CBZ and PHT, using a threshold of 15% of the patients
complaining. Results are illustrated in Table 4.
Although there were some common areas (fati-
gue/tiredness and memory difficulties), there were
also some differences: more tremor and weight gain
for VPA, more concentration difficulties for CBZ and
especially for PHT and more ataxia (co-ordination
difficulties) for PHT.
Discussion
Physicians need to be aware if their patients taking
AEDs in a routine clinical setting perceive side
effects from these drugs, even when their epilepsy
is well controlled. Our study of subjective side
effects of AEDs used a community-based approach,
taking advantage of the accurate databases of the
pharmacies in the Netherlands, attempting to avoid
as much as possible bias due to selecting patients at
clinic visits or in trials, or in epilepsy support groups.
We studied a group representative for the broad
range of patients with epilepsy, living independentlyin the community, not actively seeking care or
reporting problems. The number of 399 identified
AED users with epilepsy in an area with 107,000
inhabitants of at least 15 years yields a prevalence
rate of epilepsy of almost .4% within this area. This
illustrates that (given the exclusion of children,
patients living in institutions, and of the 5000 clients
of the pharmacy which did not contribute to our
study) the sample is probably representative as this
comes close to prevalence rates in current epide-
miological studies.7 Although precise information on
the duration of epilepsy or AED use in our respon-
dents was not known, we have no reason to expect
that the epilepsy incidence rate in this population
differed from the incidence of 50 cases per 100,000
published elsewhere, making it likely that the large
majority of respondents were on long-term AED
treatment.
Potential flaws to our study are first of all the
possible influence of non-responders and responders
who did not complete the questionnaire. In our
opinion, the data suggest that a reasonably unbiased
sample has been enrolled. An overall 72% response
to a mailed questionnaire to a heterogeneous popu-
lation seems quite acceptable.8 Basic demographic
and treatment characteristics were not different for
non-responders compared to responders. We have
no reason to assume that response rates were very
different between those with and those without
epilepsy, as those with epilepsy were left free to
return the questionnaire without answering the
questions. Patients without complaints about their
treatment may, however, have been less motivated
to complete our questionnaire. As such, we may
have overestimated the prevalence of complaints,
but given the high response rate this is not likely to
be a factor with substantial effect on the results.
Clearly, we only noted complaints in patients who
continued their medication and medically unaccep-
table side effects, such as allergic reactions usually
are a reason to discontinue medication and were not
the focus of this study.
Secondly, we had no detailed clinical informa-
tion, independent from the information provided by
the patients. Because this study was intended as a
survey of AED-associated complaints in a commu-
nity-based sample of AED users with a diagnosis of
epilepsy, we feel the lack of detailed clinical infor-
mation with respect to seizures and epilepsy does
not compromise our findings. Such information typi-
cally is only reliable when studying a (specialised)
clinic-based sample.
Finally, respondents may have been influenced by
their knowledge of the side effects profile of their
AEDs. However, there is experimental evidence sug-
gesting such influence is limited.9
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ple, treatment results in terms of seizure control
were excellent for the majority of patients: almost
half the patients had reached a 2-year seizure
remission, 81% of the patients were using mono-
therapy. Only about half the patients with ongoing
seizures (58%) considered their seizures unaccep-
table. Studies on treatment results in epilepsy have
established similar results.10 About one-third of the
patients reported not to have discussed their epi-
lepsy with his/her physician during the last year.
The latter finding probably reflects the high per-
centage of patients in seizure remission, but might
also point to a lack of expert care for some of these
patients.
The aim of our study was to evaluate patient-
reported subjective complaints about side effects of
AEDs in a community-based sample with epilepsy. In
many selected study groups of people with epilepsy,
such as epilepsy support groups,11 and in trials with
refractory patients, complaints about side effects
are frequent. Clearly, these groups may have been
biased towards treatment resistance, and it can be
expected that a community-based sample would
reveal better results. Although in our sample treat-
ment results were quite good in terms of seizure
control, side effects emerged as an important issue.
Almost 60% of the patients reported moderate/ser-
ious to very serious side effects on at least three
areas. This finding was not restricted to a specific
group, i.e. both patients in remission and patients
continuing to have seizures reported complaints. We
noted two domains in which complaints were espe-
cially frequent: general CNS-related side effects
(such as fatigue or dizziness) and cognitive side
effects. If we combine the cognitive and mood
domains, behavioural complaints were the domi-
nant complaint in our study sample. In line with
this, the most frequent separate complaints were
memory problems (21.4% of the patients) and fati-
gue (20.3%).
Comparing four major treatment groups (respec-
tively, VPA, CBZ, PHT in monotherapy, and all using
polytherapy) we found a higher percentage of com-
plaints in patients using polytherapy. Such findings
have also been reported from clinical groups,12
studies in patients with refractory epilepsy13 and
within the context of many AED trials. In addition,
we found more concentration difficulties for PHT
compared to VPA and more weight gain for both VPA
and PHT compared to CBZ.
It is often debated whether we may accept sub-
jective patients complaints at face value.4 Epilepsy
may lead to secondary impairments that may cause
subjective complaints. It is not always possible for
patients to identify the exact source of problems,and problems may thus erroneously be interpreted
by the patient as adverse effects of AEDs. Although
this may be different in patients with refractory
epilepsy and substantial comorbidity, our analysis
showed that the most frequent complaints (memory
and fatigue) had not a substantial relationship with
possible interfering factors such as frequency or
acceptability of seizures, or remission from sei-
zures. Also, if we look at the type of dominant
complaints per AED, we found profiles matching
those established in experimental studies.1,2 It
has been stated that the use of checklists to assess
side effects has the advantage of adequately
addressing specific effects, and the disadvantage
of causing overreporting.14 We are aware that some
complaints detected in our study may be attribu-
table to ‘background noise’ or comorbidity, such as
depression. It has been shown, however, that sub-
jective complaints, measured by similar checklists
as used in this study, are important determinants of
quality of life in epilepsy,11 and as such they seem
clinically relevant.
The very low proportion of respondents in our
sample taking new AEDs is first of all due to the time
of the study, with such drugs as topiramate, gaba-
pentin and levetiracetam having been registered
only recently in the Netherlands. Secondly, most
well controlled AED users in this sample would not
fulfil the criteria for prescribing new AEDs according
to present Dutch Guidelines for treating epilepsy. It
would be interesting to study if the introduction of
new AEDs with better side effects profiles would
lead to a reduction in complaints in a future study
using a similar instrument.
Our final conclusions are:- The majority of patients chronically taking AEDs
attribute complaints to their medication. Espe-
cially, behavioural side effects occurred fre-
quently and may require careful monitoring and
possible interventions.- Further studies are needed to explore the
mechanisms behind complaints as addressed in
this study and the usefulness of interventions
based on reported complaints.
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Questions about side effects of the
medication
Antiepileptic medications can cause side effects.
We would like to ask your opinion about complaints
you believe to be caused by the medication.
Would you please read the list below and give
your opinion by ticking the box in the row of your
complaints.
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